1338247-35-0

中文名稱 BMS-5

英文名稱 N-(5-(1-(2,6-dichlorophenyl)-3-(difluoroMethyl)-1H-pyrazol-5-yl)thiazol-2-yl)isobutyraMide

CAS 1338247-35-0

分子式 C17H14Cl2F2N4OS

分子量 431.29

MOL 文件 1338247-35-0.mol

更新日期 2026/05/17 14:28:34

1338247-35-0 結構式

基本信息物理化學性質安全數(shù)據(jù) 圖譜信息 BMS-5價格(試劑級) 常見問題列表

基本信息

中文別名

化合物BMS5
BMS-5游離態(tài)

英文別名

LIMKI-3
CS-2190
BMS 5
BMS5
BMS-5 ≥95%
BMS-5， LIMKI-3
LIMKI-3
BMS5
BMS 5
LIMKI3
LIMKI 3
N-(5-(1-(2,6-dichlorophenyl)-3-(difluoroMethyl)-1H-pyrazol-5-yl)thiazol-2-yl)isobutyraMide
N-[5-[1-(2,6-Dichlorophenyl)-3-(difluoromethyl)-1H-pyrazol-5-yl]-2-thiazolyl]-2-methylpropanamide
Propanamide, N-[5-[1-(2,6-dichlorophenyl)-3-(difluoromethyl)-1H-pyrazol-5-yl]-2-thiazolyl]-2-methyl-
N-{5-[1-(2,6-Dichlorophenyl)-3-(difluoromethyl)-1H-pyrazol-5-yl]- 1,3-thiazol-2-yl}-2-methylpropanamide

物理化學性質

密度1.54±0.1 g/cm3(Predicted)

儲存條件Sealed in dry,Store in freezer, under -20°C

溶解度DMSO:PBS (pH 7.2) (1:5):0.2(Max Conc. mg/mL);0.46(Max Conc. mM)
Ethanol:3.0(Max Conc. mg/mL);6.96(Max Conc. mM)

酸度系數(shù)(pKa)9.51±0.50(Predicted)

形態(tài)白色粉末

顏色White to off-white

InChI1S/C17H14Cl2F2N4OS/c1-8(2)16(26)23-17-22-7-13(27-17)12-6-11(15(20)21)24-25(12)14-9(18)4-3-5-10(14)19/h3-8,15H,1-2H3,(H,22,23,26)

InChIKeyIVUGBSGLHRJSSP-UHFFFAOYSA-N

SMILESClC1=CC=CC(Cl)=C1N2N=C(C=C2C3=CN=C(NC(C(C)C)=O)S3)C(F)F

安全數(shù)據(jù)

危險性符號(GHS) 有害 (GHS07)

GHS07

警示詞警告

危險性描述H302-H312-H332

防范說明P280

WGK GermanyWGK 2

存儲類別11 - Combustible Solids

圖譜信息

BMS-5(1338247-35-0)核磁圖(¹HNMR)

BMS-5價格(試劑級)

報價日期	產品編號	產品名稱	CAS號	包裝	價格
2026/03/03	S0185	BMS-5 BMS-5	1338247-35-0	5mg	857.46元
2026/03/03	S0185	BMS-5 BMS-5	1338247-35-0	25mg	1775.47元
2026/03/03	S0185	BMS-5	1338247-35-0	100mg	6855.74元

常見問題列表

生物活性

BMS-5 (LIMKi 3) 是一種有效的 LIM kinases (LIMK) 的抑制劑，對LIMK1和LIMK2的IC50值分別為7 nM和8 nM。

靶點

Target	Value
LIMK1 (Cell-free assay)	7 nM
LIMK2 (Cell-free assay)	8 nM

體外研究

BMS-5 (LIMKi 3) inhibits cofilin-Ser3 phosphorylation in a dose-dependent manner in Nf2 ^ΔEx2 mouse Schwann cells (MSCs) with an IC ₅₀ of ~2 μM. BMS-5 (LIMKi 3) reduces Nf2 ^ΔEx2 MSC viability in a dose-dependent manner with an IC ₅₀ of 3.9 μM, but does not significantly reduce the viability of control Nf2 ^flox2/flox2 MSCs at equivalent BMS-5 concentrations. At 10 μM BMS-5, Nf2 ^ΔEx2 MSC viability is 40% compared to 83% for controls.

體內研究

BMS-5 (LIMKi 3) (20 or 200 μM/side) is bilaterally infused into the hippocampus of rats immediately after contextual fear conditioning training. Rats are tested for memory consolidation 48 h after fear conditioning. Post hoc analysis shows that the group treated with 200 μM BMS-5 express lower freezing levels compared to the 20 μM and vehicle groups (P<0.01).